Please use this identifier to cite or link to this item:
Title: Future options of anti-angiogenic cancer therapy.
Authors: Cao, Yihai
First Published: 15-Feb-2016
Publisher: BioMed Central
Citation: Chinese Journal of Cancer, 2016, 35 (1), 21
Abstract: In human patients, drugs that block tumor vessel growth are widely used to treat a variety of cancer types. Many rigorous phase 3 clinical trials have demonstrated significant survival benefits; however, the addition of an anti-angiogenic component to conventional therapeutic modalities has generally produced modest survival benefits for cancer patients. Currently, it is unclear why these clinically available drugs targeting the same angiogenic pathways produce dissimilar effects in preclinical models and human patients. In this article, we discuss possible mechanisms of various anti-angiogenic drugs and the future development of optimized treatment regimens.
DOI Link: 10.1186/s40880-016-0084-4
ISSN: 1000-467X
eISSN: 1944-446X
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2016, the author. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http:// ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( zero/1.0/ ) applies to the data made available in this article, unless otherwise stated.
Appears in Collections:Published Articles, Dept. of Cardiovascular Sciences

Files in This Item:
File Description SizeFormat 
Future options of anti-angiogenic cancer therapy..pdfPublished (publisher PDF)1.69 MBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.